Levosimendan Accord (Levosimendan)

Levosimendan works by binding to troponin C in cardiac muscle, increasing its sensitivity to calcium and thereby strengthening contractions without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in blood vessels, causing vasodilation and lowering cardiac workload.

The dosage of Levosimendan Accord is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The prescriber sets the infusion rate and duration according to approved guidelines and individual therapeutic needs.

Safety data for levosimendan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike traditional inotropes that increase intracellular calcium, levosimendan enhances contractility by sensitizing troponin C, which may reduce calcium‑related toxicity. It also provides vasodilatory effects, offering a combined inotropic‑vasodilatory profile that can be advantageous in certain heart‑failure scenarios.

Levosimendan Accord should be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution to maintain stability.

Levosimendan Accord is given as an intravenous infusion. The infusion is typically started under continuous cardiac and hemodynamic monitoring in a hospital setting, with the rate adjusted according to the patient’s response and clinical guidelines.

The most serious risks include severe hypotension, ventricular arrhythmias, and myocardial ischemia. Patients should be closely monitored for blood pressure drops and abnormal heart rhythms throughout the infusion and for a period after discontinuation.

Levosimendan is contraindicated in patients with uncontrolled severe hypotension, known hypersensitivity to the drug, or those receiving other potent vasodilators that could precipitate dangerous blood‑pressure falls. Clinical judgment is required to assess suitability for each individual.